South Delhi Pharma, New Delhi, India
TRODELVY ™ (sacituzumab govitecan-hziy) for injection, for intravenous use.
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email firstname.lastname@example.org to discuss.
TRODELVY is a prescription medicine. TRODELVY is used to treat triple-negative breast cancer
INDICATIONS AND USAGE
TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two
prior therapies for metastatic disease. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE FORMS & STRENGTHS
For injection: 180 mg lyophilized powder in single-dose vials for econstitution.
Manufactured By: Immunomedics, Inc
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “TRODELVY ™ (sacituzumab govitecan-hziy) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate for the treatment of adults with triple-negative breast cancer (TNBC) that has spread to other parts of the body and have received at least two prior therapies.
Sacituzumab govitecan has a boxed warning about the risk of severe neutropenia (abnormally low levels of white blood cells) and severe diarrhea.
Sacituzumab govitecan may cause harm to a developing fetus or newborn baby.